

*Claims*

1. Adamantan ammonium salts of 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole (omeprazole) and of (*S*)-5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole (esomeprazole).  
5
2. The adamantan ammonium salt according to claim 1 wherein the salt is 1-adamantan ammonium salt of omeprazole.
- 10 3. The adamantan ammonium salt according to claim 1 wherein the salt is 1-adamantan ammonium salt of esomeprazole.
4. The adamantan ammonium salt according to any of claims 1, wherein the salt is 2-adamantan ammonium salt of omeprazole.
- 15 5. The adamantan ammonium salt according to claim 1, wherein the salt is 2-adamantan ammonium salt of esomeprazole.
6. The adamantan ammonium salts according to any of claims 1 to 5 characterized in  
20 that the compound is crystalline.
7. A process for preparation of an adamantan ammonium salt of omeprazole and of esomeprazole, according to any of claims 1 to 6, which comprises the following steps:
  - a) dissolving omeprazole or esomeprazole in an organic solvent;
  - 25 b) adding an adamantan amine and precipitating the desired salt;
  - c) isolating and drying of the obtained salt of omeprazole or esomeprazole.
8. The process according to claim 7 wherein the organic solvent is selected from acetonitril, ethylacetate, *tert*-butyl methyl ether and methanol, or a mixture thereof.

9. The process according to claim 7 wherein the organic solvent is selected from acetonitril, ethylacetate and methanol, or mixtures thereof.

10. The process according to any of claims 7 to 9 wherein an adamantan ammonium salt of omeprazole is obtained.

11. The process according to any of claims 7 to 9 wherein an adamantan ammonium salt of esomeprazole is obtained.

12. A pharmaceutical composition comprising the adamantan ammonium salt of omeprazole or esomeprazole according to any of claims 1 to 6 as active ingredients in association with pharmaceutically acceptable excipients and optionally other therapeutic ingredients.

13. Use of the adamantan ammonium salt of omeprazole or esomeprazole according to any of claims 1 to 6 for the manufacture of a medicament for use in the treatment of gastric acid related condition.

14. A method for treatment of a gastric acid related condition which method comprised administering to a subject suffering from said condition a therapeutically effective amount of the adamantan ammonium salt of omeprazole or esomeprazole according to any of claims 1 to 6.